ASX Announcement CLEO Establishes U.S. Lab Infrastructure Ahead of Clinical Validation Highlights • CLEO has commenced preparations for Clinical Validation (CV), the ?nal major clinical testing program supporting its FDA 510(k) submission • Clinical testing infrastructure established at...
CLEO Advances Toward Clinical Validation
Filed with ASX · · 3 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced the establishment of its U.S. laboratory infrastructure for Clinical Validation of its Pre-Surgical Ovarian Cancer Test, which is a key step in its FDA submission process. The Clinical Validation program will involve testing a significant number of samples across various study populations to assess the test's clinical performance. Testing is expected to begin shortly, following the receipt of test kits at the laboratory. This announcement outlines the preparations and infrastructure necessary for the final major clinical testing program supporting CLEO's regulatory pathway.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from CLEO Diagnostics
- Quarterly activities and cashflow report
- CLEO Screening Test Meets Rigorous Performance Targets
- CLEO Commences Analytical Validation Ahead of FDA Submission
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Ovarian Cancer Screening Test Development
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics